Adaptimmune Ther ADR (ADAP)

$0.06 0.00 (-2.74%)
Market Cap 15.51M
Revenue (ttm) 178.03M
Net Income (ttm) -70.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.77%
Debt to Equity Ratio -0.36
Volume 26,600,100
Avg Vol 36,057,512
Day's Range N/A - N/A
Shares Out 265.05M
Stochastic %K 13%
Beta 2.18
Analysts Hold
Price Target $0.96

Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the t...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 12 3543 0000
Address:
60 Jubilee Avenue, Milton Park, Abingdon, United Kingdom
sullivan1
sullivan1 Aug. 23 at 4:18 AM
$ADAP
1 · Reply
blitz678
blitz678 Aug. 23 at 3:28 AM
$ADAP you've all been corn hauled
0 · Reply
blitz678
blitz678 Aug. 23 at 3:26 AM
$ADAP your fucked
1 · Reply
Knowledgeworthmore
Knowledgeworthmore Aug. 23 at 3:25 AM
$BTAI $PGEN $ADAP did ernesto got banned for false info ?? poor ernesto.
1 · Reply
BestNwest
BestNwest Aug. 23 at 3:21 AM
$ADAP letsgo to .10$
0 · Reply
SUPERMAN9454
SUPERMAN9454 Aug. 22 at 11:28 PM
$ADAP $TNFA $WLGS $GWAV Made a good $1,650 today. Good is good! Find your niche and stick to it! 🚀🏎️🤤💰
0 · Reply
SUPERMAN9454
SUPERMAN9454 Aug. 22 at 11:09 PM
$ADAP $TNFA $ZNGA Dinner is served!!! 📈✌🏼🏎️
1 · Reply
F001SGold
F001SGold Aug. 22 at 10:15 PM
$ADAP ...and at 5:57pm the same poster writes: "... false gods who also only lie like printed.... but ADAP will rise even without such showmen ! the reversal is going on NOW . Bullish
0 · Reply
Wallstreetbeagle
Wallstreetbeagle Aug. 22 at 9:31 PM
$ADAP Der beagle is here. He has a clue. The same as ixhl bevor explode. It smells good!
0 · Reply
SUPERMAN9454
SUPERMAN9454 Aug. 22 at 9:28 PM
$ADAP Who else caught that dip? 😂😂😂📈✌🏼
0 · Reply
Latest News on ADAP
Adaptimmune Reports Q2 Financial Results and Provides Business Update

Aug 13, 2025, 7:30 AM EDT - 9 days ago

Adaptimmune Reports Q2 Financial Results and Provides Business Update

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Jul 28, 2025, 7:30 AM EDT - 25 days ago

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript

May 13, 2025, 1:59 PM EDT - 3 months ago

Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript

Adaptimmune Reports Q1 Financial Results and Provides Business Update

May 13, 2025, 7:30 AM EDT - 3 months ago

Adaptimmune Reports Q1 Financial Results and Provides Business Update

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

May 7, 2025, 12:00 PM EDT - 3 months ago

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 12:10 PM EDT - 5 months ago

Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Mar 20, 2025, 7:00 AM EDT - 5 months ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Mar 12, 2025, 4:54 PM EDT - 5 months ago

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Jan 30, 2025, 4:00 PM EST - 7 months ago

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Jan 13, 2025, 8:00 AM EST - 7 months ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Dec 19, 2024, 7:30 AM EST - 8 months ago

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Dec 2, 2024, 4:00 PM EST - 9 months ago

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:48 PM EST - 10 months ago

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Adaptimmune Reports Q3 2024 Financial and Business Updates

Nov 13, 2024, 4:05 PM EST - 10 months ago

Adaptimmune Reports Q3 2024 Financial and Business Updates

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Nov 13, 2024, 9:00 AM EST - 10 months ago

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Nov 5, 2024, 9:19 AM EST - 10 months ago

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Oct 31, 2024, 5:20 PM EDT - 10 months ago

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Adaptimmune to Participate in Two Bank Conferences this September

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Adaptimmune to Participate in Two Bank Conferences this September

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 11:42 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Adaptimmune Reports Q2 2024 Financial and Business Updates

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Reports Q2 2024 Financial and Business Updates

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

US FDA approves Adaptimmune's gene therapy for rare type of cancer

Aug 2, 2024, 9:20 AM EDT - 1 year ago

US FDA approves Adaptimmune's gene therapy for rare type of cancer

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Aug 1, 2024, 8:20 PM EDT - 1 year ago

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 3, 2024, 9:54 AM EDT - 1 year ago

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Jun 17, 2024, 2:05 PM EDT - 1 year ago

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Jun 3, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

May 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

GLPG

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

May 30, 2024, 4:01 PM EDT - 1 year ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

GLPG

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

May 15, 2024, 10:07 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

Adaptimmune Reports Q1 2024 Financial and Business Updates

May 15, 2024, 7:30 AM EDT - 1 year ago

Adaptimmune Reports Q1 2024 Financial and Business Updates

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

May 15, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

HTGC

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

May 1, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26, 2024, 11:00 AM EDT - 1 year ago

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Mar 27, 2024, 7:30 PM EDT - 1 year ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 9:29 AM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Mar 6, 2024, 7:00 AM EST - 1 year ago

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Feb 27, 2024, 8:00 AM EST - 1 year ago

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Feb 21, 2024, 4:00 PM EST - 1 year ago

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Jan 31, 2024, 4:44 PM EST - 1 year ago

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Jan 4, 2024, 7:37 AM EST - 1 year ago

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Dec 6, 2023, 7:00 AM EST - 1 year ago

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Adaptimmune Receives Transfer of IND for Lete-cel Program

Nov 29, 2023, 8:00 AM EST - 1 year ago

Adaptimmune Receives Transfer of IND for Lete-cel Program

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 11:45 AM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript

Adaptimmune Reports Third Quarter Financial Results and Business Update

Nov 8, 2023, 7:30 AM EST - 1 year ago

Adaptimmune Reports Third Quarter Financial Results and Business Update

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Nov 8, 2023, 7:05 AM EST - 1 year ago

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Oct 25, 2023, 8:06 AM EDT - 1 year ago

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

Oct 23, 2023, 4:15 AM EDT - 1 year ago

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

sullivan1
sullivan1 Aug. 23 at 4:18 AM
$ADAP
1 · Reply
blitz678
blitz678 Aug. 23 at 3:28 AM
$ADAP you've all been corn hauled
0 · Reply
blitz678
blitz678 Aug. 23 at 3:26 AM
$ADAP your fucked
1 · Reply
Knowledgeworthmore
Knowledgeworthmore Aug. 23 at 3:25 AM
$BTAI $PGEN $ADAP did ernesto got banned for false info ?? poor ernesto.
1 · Reply
BestNwest
BestNwest Aug. 23 at 3:21 AM
$ADAP letsgo to .10$
0 · Reply
SUPERMAN9454
SUPERMAN9454 Aug. 22 at 11:28 PM
$ADAP $TNFA $WLGS $GWAV Made a good $1,650 today. Good is good! Find your niche and stick to it! 🚀🏎️🤤💰
0 · Reply
SUPERMAN9454
SUPERMAN9454 Aug. 22 at 11:09 PM
$ADAP $TNFA $ZNGA Dinner is served!!! 📈✌🏼🏎️
1 · Reply
F001SGold
F001SGold Aug. 22 at 10:15 PM
$ADAP ...and at 5:57pm the same poster writes: "... false gods who also only lie like printed.... but ADAP will rise even without such showmen ! the reversal is going on NOW . Bullish
0 · Reply
Wallstreetbeagle
Wallstreetbeagle Aug. 22 at 9:31 PM
$ADAP Der beagle is here. He has a clue. The same as ixhl bevor explode. It smells good!
0 · Reply
SUPERMAN9454
SUPERMAN9454 Aug. 22 at 9:28 PM
$ADAP Who else caught that dip? 😂😂😂📈✌🏼
0 · Reply
Knowledgeworthmore
Knowledgeworthmore Aug. 22 at 9:18 PM
$ADAP im positive.
0 · Reply
Wallstreetbeagle
Wallstreetbeagle Aug. 22 at 9:10 PM
$ADAP To short it, is a genocide. A Skyfall for people with cancer! Whoever destroys this take life!
0 · Reply
NIVOLOCO
NIVOLOCO Aug. 22 at 8:58 PM
$ADAP 🔥
0 · Reply
Wallstreetbeagle
Wallstreetbeagle Aug. 22 at 8:31 PM
$ADAP Help for people they have cancer is garbage? I puke! Would it be an arms deal, hurray. Shame on you.
1 · Reply
Felixii
Felixii Aug. 22 at 8:29 PM
$ADAP only way up
0 · Reply
Spikus
Spikus Aug. 22 at 8:24 PM
$ADAP garbage
0 · Reply
Knowledgeworthmore
Knowledgeworthmore Aug. 22 at 8:20 PM
$ADAP thats why lm going to keep adding.
1 · Reply
Wallstreetbeagle
Wallstreetbeagle Aug. 22 at 8:15 PM
$ADAP They fight against cancer. With own therapie. Cancer is the realy pandemie. Unfortunately a big market. Here is help! Take this!
1 · Reply
spokes
spokes Aug. 22 at 8:01 PM
$ADAP some reason they didnt want it green on the day?
0 · Reply
spokes
spokes Aug. 22 at 7:56 PM
$ADAP Thats a BIG wall at .0580
1 · Reply
Wallstreetbeagle
Wallstreetbeagle Aug. 22 at 7:55 PM
$ADAP IXHL increased from 0,08 to 0,22 and than to 1,70. For example.
0 · Reply
sullivan1
sullivan1 Aug. 22 at 7:53 PM
$ADAP This is $IXHL in making imo
1 · Reply